Bio NTech SE

GPTKB entity

Statements (62)
Predicate Object
gptkbp:instance_of gptkb:biotechnology
gptkbp:acquisition Pfizer collaboration
gptkbp:awards gptkb:TIME_100_Most_Influential_People_(2021)
gptkbp:ceo gptkb:Uğur_Şahin
gptkbp:clinical_stage Phase 3
gptkbp:clinical_trial gptkb:vaccine
cancer vaccines
influenza vaccine
malaria vaccine
HIV vaccine
Zika virus vaccine
autoimmune disease therapies
TB vaccine
cardiovascular diseases therapies
chronic diseases therapies
infectious diseases therapies
neurodegenerative diseases therapies
rare diseases therapies
vaccine development for emerging diseases
gptkbp:collaboration gptkb:Moderna
gptkb:Fosun_Pharma
gptkbp:collaborations gptkb:Max_Planck_Institute
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_California
gptkb:University_of_Pennsylvania
gptkb:National_Institutes_of_Health
gptkb:Weill_Cornell_Medicine
gptkb:Yale_University
gptkb:Karolinska_Institute
gptkb:MIT
gptkbp:employees over 1,500
gptkbp:focus_area m RNA technology
gptkbp:founded gptkb:2008
gptkbp:founder gptkb:Özlem_Türeci
gptkb:Uğur_Şahin
gptkbp:headquarters gptkb:Mainz,_Germany
https://www.w3.org/2000/01/rdf-schema#label Bio NTech SE
gptkbp:industry gptkb:pharmaceuticals
gptkbp:invention m RNA technology patents
gptkbp:investment Venture capital
$1.5 billion (2020)
gptkbp:market_cap approximately $20 billion
gptkbp:notable_products gptkb:BNT162b2
gptkbp:partnership gptkb:Sanofi
gptkb:Pfizer
gptkb:Cure_Vac
gptkbp:product gptkb:Comirnaty
gptkbp:publicly_traded gptkb:NASDAQ
gptkbp:research_focus cancer immunotherapy
gptkbp:research_institutes gptkb:University_of_Mainz
gptkbp:revenue $18.9 billion (2021)
gptkbp:stock_symbol gptkb:BNTX
gptkbp:subsidiary gptkb:Bio_NTech_RNA_Pharmaceuticals
gptkbp:technology lipid nanoparticles
gptkbp:vaccine_type gptkb:vaccine
gptkbp:website biontech.de
gptkbp:bfsParent gptkb:Pfizer-Bio_NTech
gptkb:Frankfurt_Stock_Exchange
gptkb:Bio_NTech
gptkbp:bfsLayer 5